1stOncology™: Cancer Intelligence Service – Page 81 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities

On May 27, 2026 Panome Bio, a leading multi-omics contract research organization (CRO) and CLIA-certified laboratory, and TD2 Oncology, a globally recognized oncology-focused CRO specializing in preclinical and clinical drug development, reported an expansion of their strategic partnership. The collaboration establishes a coordinated framework that gives researchers access to translational oncology expertise, clinical development, and comprehensive multi-omics analysis under a connected program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The partnership pairs TD2’s deep expertise in translational and clinical oncology with Panome Bio’s capabilities in metabolomics, proteomics, transcriptomics and exposomics. By aligning these strengths, the two organizations provide researchers with a more connected approach to studying cancer biology and therapeutic response, from research models through clinical trials.

TD2 is a widely recognized leader in translational oncology research and clinical development, with platforms designed to evaluate therapeutic candidates in clinically relevant settings. By integrating Panome Bio’s multi-omics technologies into this ecosystem, researchers can now connect therapeutic outcomes with broad molecular measurements spanning metabolism, protein signaling, gene expression, and environmental exposures. This combined approach supports biomarker discovery, mechanisms associated with sensitivity or resistance to treatment and a more detailed understanding of cancer biology during drug development.

"Modern oncology research generates enormous amounts of biological data spanning model development through clinical trials, but translating those findings into a deeper molecular understanding remains a major challenge," said Edward Weinstein, CEO of Panome Bio. "Working with TD2 allows us to pair their expertise across translational and clinical oncology with comprehensive multi-omics profiling. This will help to better characterize therapeutic response and connect biology across every stage of development."

"Our focus has always been optimizing oncology programs in moving efficiently from translational development into the clinic," said Stephen Gately, CEO of TD2 Oncology. "No other oncology CRO can offer this combination of translational and clinical expertise alongside this depth of molecular profiling. This partnership gives drug developers a direct connection between therapeutic outcomes and the molecular data needed to understand them".

The partnership is particularly well-suited to biomarker discovery, mechanism-of-action studies, evaluation of drug resistance and characterization of biological variability in therapeutic response. By integrating molecular data across multiple molecular and biological layers, researchers can identify signatures associated with treatment sensitivity, resistance, toxicity, and patient stratification that may not be apparent through single-modality analysis alone. These capabilities can support clinical development efforts by improving patient selection strategies, informing biomarker-driven trial design, and helping sponsors better understand variability in clinical outcomes. The partnership is available immediately to researchers seeking coordinated multi-omics support spanning translational research through clinical development.

(Press release, TD2, MAY 27, 2026, View Source [SID1234666138])

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

On May 27, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported significant progress in the development of ERNA-101, the company’s lead therapeutic candidate, achieving multiple critical milestones that position the program for a planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study.

The company has successfully completed process development activities for the ERNA-101 manufacturing process and has now transitioned into Good Manufacturing Practice (GMP) manufacturing in preparation for clinical development. In parallel, technology transfer activities for ERNA-101 are actively underway, representing another major operational milestone supporting the planned IND submission timeline.

"These achievements represent a defining moment for Ernexa Therapeutics," said Sanjeev Luther, CEO of Ernexa Therapeutics. "Completing process development and advancing into GMP manufacturing are critical steps toward IND clearance and the launch of our first-in-human clinical study for ERNA-101. We are executing against our development strategy with urgency and discipline and remain firmly on track for our planned IND filing in the third quarter of 2026, Most importantly, we believe ERNA-101 has the potential to bring new hope to patients and families in need of better therapeutic options."

The advancement of ERNA-101 reflects continued momentum across the company’s development and manufacturing operations and marks an important evolution in Ernexa’s corporate trajectory toward becoming a clinical-stage biotechnology company.

"With technology transfer now in progress and manufacturing activities advancing as planned, we believe Ernexa is entering a transformational phase," added CEO, Sanjeev Luther. "These milestones will significantly strengthen our operational readiness and reinforce our confidence in the path toward clinical evaluation of ERNA-101."

ERNA-101 is being advanced as part of Ernexa Therapeutics’ broader mission to develop innovative therapies designed to address significant unmet medical needs.

Key Highlights

IND submission for ERNA-101 targeted for Q3 2026
Technology transfer activities currently in progress
Process development for ERNA-101 manufacturing successfully completed
Transition to GMP manufacturing underway in preparation for clinical studies
Company advancing toward anticipated transformation into a clinical-stage biotechnology company
Progress supports planned first-in-human clinical study following IND clearance

(Press release, Ernexa Therapeutics, MAY 27, 2026, View Source [SID1234666137])

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

On May 27, 2026 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reported it will share data demonstrating the utility of Myriad’s Precise MRD (molecular residual disease) test across diverse cancer types.

Myriad will share evidence across six poster presentations showcasing the prognostic power of its ultrasensitive MRD assay. Several of the presentations report interim outcomes from the groundbreaking MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, National Cancer Center Hospital East, Japan. "MONSTAR-SCREEN-3 has demonstrated exceptional performance of Precise MRD across more than a dozen indications," said Dr. Yoshino. "In our presentation, ’Prognostic Impact of MRD Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3,’ we report 97% baseline detection, with 16% of samples detected in the ultrasensitive range. Importantly, patients who were ctDNA-positive at one month post-surgery had significantly worse disease-free survival compared to those who were ctDNA-negative, suggesting that post-surgical ctDNA positivity, including at ultrasensitive levels, is strongly prognostic for recurrence risk."

Other presentations focused on ovarian cancer, gastric cancer, head and neck cancer, and sarcoma also demonstrate the emerging clinical utility of ctDNA as a biomarker of recurrence and therapy response. "Our findings highlight the clear advantage of a whole-genome, personalized MRD approach in capturing clinically meaningful signals at the lowest ctDNA levels," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. "Detecting ctDNA at very low levels consistently across multiple tumor types demonstrates that sensitivity truly matters. Precise MRD may enable a new standard in which ultra-sensitive detection translates directly into earlier, more confident clinical decision-making."

Attendees can meet Dr. Muzzey at the Industry Expert Theater #1 on Sun., May 31 from 9:30 to 10:30 am CDT for an introduction to the Precise MRD Test. The session will cover assay technical details and the clinical evidence across multiple solid tumors, including breast and colorectal cancers, and explore the role of highly sensitive MRD detection in oncology.

Myriad Presentations
Poster 64, abstract 4081: Whole-Genome Sequencing-Based Ultra-sensitive ctDNA Molecular Residual Disease Assessment in Resectable Gastric Cancer: Results from MONSTAR-SCREEN-3
Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sat., May 30, 9:00 am–12:00 pm CDT

Poster 181, abstract 3044: Prognostic Impact of Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3
Poster Session: Developmental Therapeutics
Sat., May 30, 1:30-4:30 pm CDT

Poster 523, abstract 6066: Clinical Validation of Ultra-Sensitive WGS-based MRD Detection in Head and Neck Squamous Cell Carcinoma: Results from MONSTAR-SCREEN-3
Poster Session: Head and Neck Cancer
Sat., May 30, 1:30–4:30 pm CDT

Poster 270, abstract 5604: The Use of Circulating Tumor DNA to Stratify the Risk of Recurrence After Surgical Debulking in Epithelial Ovarian Cancer
Poster Session: Gynecologic Cancer
Mon., June 1, 9:00 am–12:00 pm CDT

Poster 334, abstract 11544: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable Sarcoma in MONSTAR-SCREEN-3
Poster Session: Sarcoma
Mon., June 1, 1:30 – 4:30 pm CDT

Poster 501, abstract 10540: Association between physical activity and molecular residual disease clearance in postoperative cancer patients: The SCRUM-MONSTAR LIFELOG study
Poster Session: Prevention, Risk Reduction, and Genetics
Mon., June 1, 2026, 1:30pm – 4:30pm CDT

Conference Highlights
Myriad will welcome attendees to its booth (#25081) during exhibition hours. Myriad tests to be highlighted at the booth include:

Precise MRD (Molecular Residual Disease) Test is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity.1 The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance.
MyRisk Hereditary Cancer Test with RiskScore combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management.
Prolaris + AI Prostate Cancer Prognostic Test is the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology from Myriad’s partnership with PATHOMIQ AI.

The booth will also feature Myriad’s Biopharma services which are utilized for working in conjunction with Biopharma partners to advance drug development programs from biomarker discovery through CTA, CDx development, worldwide regulatory approval and global commercialization, including:

MyChoice CDx is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO (Free ASCO Whitepaper) guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors.1 By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings.
MSK-ACCESS is a comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK). The test offers noninvasive cancer genomic profiling and disease monitoring using cell-free DNA (cfDNA) obtained from blood and other body fluids. The test is currently available for use in conjunction with Myriad’s Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS.
MSK-IMPACT is a solid tumor test for comprehensive genomic profiling (CGP) which delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow. The test is currently available for use in conjunction with Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS.

Stop by Myriad booth #25081 to learn more or request a dedicated meeting at the show.

About the MONSTAR-SCREEN-3 Study
The MONSTAR-SCREEN-3 is a prospective multicenter study targeting more than 1,100 patients with solid tumors undergoing curative-intent treatment. Personalized panels were constructed using Precise MRD, incorporating up to 1,000 tumor-specific alterations identified through WGS of matched tumor tissue. Serial plasma samples were collected at baseline, post-neoadjuvant treatment (NAT) (when applicable), 1-month (1M) post-surgery, every 3 months in year 1, and every 6 months thereafter up to 2 years. Assay performance was evaluated across multiple cancer types for ctDNA detection and recurrence monitoring.

About Precise MRD
The Precise MRD test provides molecular insights across the cancer care continuum. After diagnosis, the test can help clinicians determine if adjuvant treatment is needed, or if cancer has recurred. Should cancer metastasize in a patient, Precise MRD can provide molecular insights showing whether treatment is working or if a patient’s ctDNA is increasing. For baseline tests, a personalized panel is developed based on a whole-genome sequencing profile of tumor tissue, and then the panel is used to measure the ctDNA level from an initial blood draw. For ongoing monitoring, the panel measures ctDNA levels from samples collected with a frequency based on where patients are in the treatment process. Clinicians will receive an easy-to-read report that shows whether ctDNA was detected or not. If ctDNA is detected, the concentration of ctDNA is reported, which allows clinicians to see historical results of the patient’s ctDNA concentration over time. Learn more at myriad.com/oncology/precise-mrd-test/.

(Press release, Myriad Genetics, MAY 27, 2026, View Source [SID1234666136])

InnoCare Announces Approval of Orelabrutinib in Australia

On May 27, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, reported that orelabrutinib (HIBRUKA) has been approved by the Therapeutic Goods Administration (TGA) in Australia, offering a new treatment option for patients with Mantle Cell Lymphoma (R/R MCL) in the region.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, "The approval of orelabrutinib in Australia marks another important milestone in InnoCare’s global footprint and brings a new treatment option to patients with lymphoma in the region. Beyond oncology, we are also advancing global clinical trials of orelabrutinib in autoimmune diseases."

MCL is a distinct subtype of B-cell non-Hodgkin’s lymphoma (NHL). It is an aggressive and currently incurable disease with rising incidence rate. Patients are often diagnosed at an advanced stage with limited treatment options and poor prognosis.

Orelabrutinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. With its high target selectivity, it minimizes off-target effects, thereby improving both safety and efficacy.

Orelabrutinib has been approved in Singapore for the treatment of patients with R/R MCL and R/R MZL (marginal zone lymphoma). In China, Orelabrutinib has been approved for the treatment of four lymphoma indications, all of which have been included in China’s National Reimbursement Drug List.

(Press release, InnoCare Pharma, MAY 27, 2026, View Source [SID1234666135])

Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics

On May 27, 2026 Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, reported the close of its seed financing. The close brings total capital raised to $6 million since the company’s founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.

Proceeds will support continued development of the company’s lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming, where mRNA-encoded gene combinations, delivered directly into the tumor, activate the immune system by inducing antigen-presenting function in tumor cells. This approach is designed to transform the immunosuppressive tumor microenvironment into a site of active immune priming, with the goal of generating systemic antitumor immune responses.

"Many solid tumors remain difficult to treat despite advances in immunotherapy," said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. "Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents."

"This is a first-in-class approach to a problem that kills 10 million people a year, built by founders who moved from concept to in vivo data in six months with unparalleled capital efficiency," said Colin Greenspon, co-founder and partner at Narya. "That’s the kind of team and science Narya was built to back."

Reprogram identifies and prioritizes therapeutic reprogramming candidates with CellRecodeX, its AI discovery engine. CellRecodeX integrates multiple biological foundation models and is designed to support candidate nomination and pipeline expansion across indications.

(Press release, Reprogram Biosciences, MAY 27, 2026, View Source [SID1234666134])